


	Liquid SCIg								Lyophilized	
	Cutaquig	Cuvitru	Gammagard Liquid	Gammaked	Gamunex-C	Hizentra	HyQvia	Xembify	Gammagard S/D	
Manufacturer	Pfizer	Takeda	Takeda	Kedrion	Grifols	CSL Behring	Takeda	Grifols	Takeda	
Clinical Contact	1-888-429-4535	1-877-825-3327	1-877-825-3327	1-855-353-7466	1-800-520-2807	1-800-504-5434	1-877-825-3327	1-800-520-2807	1-877-825-3327	
Labeled Uses	PIDD in pts ≥ 2 y/o	PIDD in pts ≥ 2 y/o	PIDD in pts ≥ 2 y/o	PIDD in pts ≥ 2 y/o	PIDD in pts ≥ 2 y/o	PIDD in pts ≥ 2 y/o, CIDP in adults	PIDD in pts ≥ 2 y/o CIDP in adults	PIDD in pts ≥ 2 y/o	PIDD in pts ≥ 2 y/o and adults, ITP in adults, CLL, Kawasaki Syndrome in pediatric patients	
Vial Sizes	1 g, 2 g, 4 g, 8 g	1 g, 2 g, 4 g, 8 g, 10 g	1 g, 2.5 g, 5 g, 10 g, 20 g, 30 g	1 g, 2.5 g, 5 g, 10 g, 20 g	1 g, 2.5 g, 5 g, 10 g, 20 g, 40 g	Prefilled syringes: 1 g, 2 g, 4 g, 10 g Vials: 1 g, 2 g, 4 g, 10 g	2.5 g/200 U, 5 g/400 U, 10 g/800 U, 20 g/1,600 U, 30 g/2,400 U	1 g, 2 g, 4 g, 10 g	5 g, 10 g	
Diluent	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	<ul style="list-style-type: none">Sterile water96 mL for 5 gm 5%192 mL for 10 gm 5%	
Concentration	16.5%	20%	10%	10%	10%	20%	10%	20%	<ul style="list-style-type: none">5%10%: Use half diluent supplied	
Dose Conversion Factor	1.3	1.3	1.37	1.37	1.37	PIDD: 1.37, CIDP: 0.2g/kg per week initial	None	1.37		
Infusion Rate (*Refer to package insert for renally compromised or high-risk patients)	Adults ≥17 years: Infusions 1–2: ≤20 mL/hr/site. Subsequent Infusions: Gradually increase as tolerated by approximately 10 mL/hr/ site every 2-4 weeks up to a maximum of 52 mL/hr/site. Age 2-16 years: Infusions 1-2: ≤15 mL/hr/site. Subsequent Infusions: Gradually increase as tolerated by approximately 10 mL/hr/site every 2-4 weeks up to a maximum of 25mL/ hr/site.	May administer in up to 4 sites simultaneously. First 2 infusions: <40 kg administer ≤20 mL/site at rate of 10-20 mL/hr/site ≥40 kg administer ≤60 mL/site at rate of 10-20 mL/hr/site Subsequent infusions (all weights): Administer ≤60 mL/ site at rate of ≤60 mL/ hr/site	40 kg BW and greater: First infusion 30 mL/ site at a rate of 20 mL/hr/site. Subsequent doses may be increased to 30 mL/site at a rate of 20–30 mL/hr/site. Maximum flow rate not to exceed 240 mL/hr for all sites combined. Under 40 kg BW: First infusion 20 mL/site at a rate of 15 mL/hr/site. Subsequent doses may be increased to 20 mL/ site at a rate of 15–20 mL/hr/site. Maximum flow rate not to exceed 160 mL/hr for all sites combined.	Adults: 20 mL/hr/site (max of 8 infusion sites) Pediatric: Initial infusion rate: <25 kg 10 mL/hr/site, ≥25 kg 15 mL/hr/site. Maintenance infusion rate: <25 kg 10 mL/hr/ site, ≥25 kg 20 mL/hr/ site (max of 6 infusion sites)	Adults: 20 mL/hr/site (max of 8 infusion sites) Pediatric: Initial infusion rate: <25 kg 10mL/hr/site, ≥25 kg 15mL/hr/site. Maintenance infusion rate: <25 kg 10mL/hr/ site, ≥25 kg 20mL/hr/ site (max of 6 infusion sites)	PIDD: First infusion ≤15 mL/hr/site. Subsequent doses ≤25 mL/hr/site as tolerated. CIDP: First infusion ≤20 mL/hr/site. Subsequent doses ≤50 mL/hr/site as tolerated.	Refer to package insert; Initial and max rate is based on weight and number of infusions received. Infusion rates may be increased every 5–15 mins as tolerated. Initial rate range: 5–10 mL/hr/ site. Max rate: 300 mL/hr/site.	May administer up to 6 infusion sites simultaneously at a maximum rate of 25 mL/hr/site	<ul style="list-style-type: none">5%: 0.5 mL/kg/hr and may increase gradually to a maximum of 4 mL/kg/hr if no adverse reaction*High-risk patients: Maximum rate of 4 mL/kg/hr at 5%*May use 10% (if 5% tolerated)* at 0.5 mL/kg/hr and may increase gradually to 8 mL/kg/hr*	
Sugar Content	79mg/mL maltose¹	Sugar free; stabilized with glycine	Sugar free; stabilized with glycine	Sugar free; stabilized with glycine	Sugar free; stabilized with glycine	Sugar free; stabilized with L-proline	Sugar free; stabilized with glycine	Sugar free; stabilized with glycine	2% glucose	
Sodium Content	≤30mmol/L	N/A	N/A	Trace amounts	Trace amounts	Trace amounts	N/A	Trace amounts	0.85% with 5%	
Osmolality/ Osmolarity	310–380 mOsm/kg	280–292 mOsm/kg	240–300 mOsm/kg	258 mOsm/kg	258 mOsm/kg	380 mOsm/kg	240–300 mOsm/kg	280-404 mOsm/kg	5%: 636 mOsm/kg	
pH	5.0–5.5	4.6–5.1	4.6–5.1	4–4.5	4–4.5	4.6–5.2	4.6–5.1	4.1–4.8	6.8 ±0.4 (after reconstitution)	
IgA Content	206 mcg/mL	80 mcg/mL	37 mcg/mL	46 mcg/mL	46 mcg/mL	<50 mcg/mL	37 mcg/mL	<70 mcg/mL	<1 mcg/mL	
% IgG	≥96%	≥98%	>98%	>98%	>98%	≥98%	>98%	>98%	>90%	
Latex Content	Latex free	Latex free	Latex free	Latex free	Latex free	Latex free	Latex free	Latex free	Packaging contains latex	
Method of Production and Viral Inactivation/ Removal Process	Cold ethanol, pH 4.0 incubation, SD	Cold ethanol fractionation, cation and anion exchange chromatography, solvent/detergent (S/D) treatment, 35 nm nanofiltration, low pH incubation at elevated temperature	Cold ethanol fractionation, 35 nm nanofiltration, chromatography, low pH incubation, solvent/ detergent treatment	Depth filtration, cold ethanol fractionation, chromatography, low pH treatment, caprylate precipitation	Depth filtration, cold ethanol fractionation, chromatography, low pH treatment, caprylate precipitation	Depth filtration, cold alcohol fractionation, octanoic acid fractionation, chromatography, pH4 incubation, 20 nm nanofiltration	Cold ethanol fractionation, S/D treatment, 35 nm nanofiltration, low pH incubation	Cold ethanol fractionation, caprylate precipitation and filtration, and anion-exchange chromatography	Cold ethanol fractionation, ultrafiltration, chromatography, solvent/detergent treatment	
Filtration	No filter required	No filter required	In-line filter optional	No filter required	No filter required	No filter required	No filter required	No filter required	Filter required	
Flushing Compatibility	N/A	N/A	Saline or dextrose	Saline or dextrose; Do not dilute with saline	Saline or dextrose; Do not dilute with saline	N/A	Saline	Dextrose if needed	Saline or dextrose	
Storage Requirements	Store at +2°C to +8°C (36°F to 46°F) for up to 36 months from the date of manufacture. Do not use beyond the expiration date. Do not freeze. May be stored at room temp (≤25°C, 77°F) for up to 9 months without being refrigerated again during this period, and must be discarded if not used after this.	<ul style="list-style-type: none">Refrigerate or room temperatureDo not freeze	<ul style="list-style-type: none">Refrigerate or room temperatureDo not freeze	<ul style="list-style-type: none">Refrigerate or room temperatureDo not freeze	<ul style="list-style-type: none">Refrigerate or room temperatureDo not freeze	<ul style="list-style-type: none">Refrigerate or room temperatureDo not freeze	<ul style="list-style-type: none">Room temperatureDo not freezeProtect from light	<ul style="list-style-type: none">RefrigerateDo not freeze	<ul style="list-style-type: none">RefrigerateDo not freeze	<ul style="list-style-type: none">Room temperatureDo not freeze
Shelf Life		36 months refrigerated at 2°C–8°C (36°F–46°F), or up to 24 months at room temperature up to 25°C or 77°F. Do not return Cuvitru to refrigerator if you take it out to room temperature.	36 months refrigerated at 2°C–8°C (36°F–46°F), or 24 months at room temp (≤25°C, 77°F)	36 months refrigerated at 2°C– 8°C (36°F–46°F), or 6 months at room temp (≤25°C, 77°F) any time during the 36 months	36 months refrigerated at 2°C– 8°C (36°F–46°F), or 6 months at room temp (≤25°C, 77°F) any time during the 36 months	30 months when stored at room temperature as stable indicated by the expiration date on label. Preservative-free	36 months from date of manufacture refrigerated at 2°C– 8°C (36°F–46°F). Room temperature for up to 3 months during the first 24 months from the date of manufacturing printed on the carton. Hyqvia must be used within 3 months after storing at room temperature but within the expiration date on the carton and vial label.	May be stored at temperatures not to exceed 25°C (77°F) for up to 6 months any time prior to the expiration date	Store at a temperature not to exceed 25°C (77°F) for up to 24 months, preservative free	




Immunoglobulin Comparison Chart

Contact us today to learn how we can help support your Ig therapy patients.

Phone: 1-855-552-2015
Fax: 1-855-592-6889

Glossary

- CIDPChronic inflammatory demyelinating polyneuropathy
- CLLChronic lymphocytic leukemia
- Ig Immunoglobulin
- IgA Immunoglobulin A
- IgG Immunoglobulin G
- ITPImmune thrombocytopenic purpura
- IVIntravenous
- IVIg Intravenous immunoglobulin
- MMN.....Multifocal motor neuropathy
- NaCl.....Sodium chloride; saline
- PIDDPrimary immunodeficiency disease
- pHPotential of hydrogen
- SCIgSubcutaneous immunoglobulin



Visit cvs.co/ig-comparison or scan the QR code to view electronically. For easy access, you can bookmark this page.

	Liquid IVIg											
	Alyglo	Asceniv	Bivigam	Gammagard Liquid	Gammaked	Gammaplex	Gamunex-C	Octagam	Panzyga	Privigen	Yimmugo	
Manufacturer	GC Biopharma	ADMA	ADMA	Takeda	Kedrion	Kedrion	Grifols	Octapharma/Pfizer	Pfizer	CSL Behring	Kedrion	
Clinical Contact	1-833-426-6426	1-800-458-4244	1-800-458-4244	1-877-825-3327	1-855-353-7466	1-866-398-0825	1-800-520-2807	1-888-429-4535 (Octapharma)	1-888-429-4535	1-800-504-5434	1-855-353-7466	
Labeled Uses	PIDD in adults	PIDD in adults and adolescents 12–17 years of age	PIDD in pts ≥2 y/o	PIDD in pts ≥2 y/o, MMN in adults CIDP in adults	CIDP in adults, PIDD in pts ≥2 y/o, ITP in adults and children	PIDD in pts ≥2 y/o, ITP	CIDP in adults, PIDD in pts ≥2 y/o, ITP in adults and children	5%: PIDD 10%: ITP in adults, DM in adults	PIDD in pts ≥2 y/o , ITP in adults, CIDP in adults	PIDD, ITP in patients ≥15 y/o, CIDP in adults	PI in pts ≥2 y/o	
Dosing Sizes	5 g, 10 g, 20 g	5 g	5 g, 10 g	1 g, 2.5 g, 5 g, 10 g, 20 g, 30 g	1 g, 2.5 g, 5 g, 10 g, 20 g	• 5%: 5 g, 10 g, 20 g • 10%: 5 g, 10 g, 20 g	1 g, 2.5 g, 5 g, 10 g, 20 g	• 5%: 1 g, 2.5 g, 5 g, 10 g, 25 g • 10%: 2 g, 5 g, 10 g, 20 g, 30 g	1 g, 2.5 g, 5 g, 10 g, 20 g, 30 g	5 g, 10 g, 20 g, 40 g	5 g, 10 g, 20 g	
Concentration	10%	10%	10%	10%	10%	5%, 10%	10%	5%, 10%	10%	10%	10%	
Infusion Rate *Refer to package insert for renally compromised or high-risk patients	<ul style="list-style-type: none">Initial Infusion Rate 1st Infusion: 1 mg/kg/min (0.01 mL/kg/min)Maintenance Infusion Rate 1st Infusion: Double the infusion rate every 30 minutes (if tolerated) up to 8 mg/kg/min (0.08 mL/kg/min)Initial Infusion Rate from 2nd Infusion: 2 mg/kg/min (0.02 mL/kg/min)Maintenance Infusion Rate from 2nd Infusion: Double the infusion rate every 15 minutes (if tolerated) up to 8 mg/kg/min (0.08 mL/kg/min)	<ul style="list-style-type: none">Initial Infusion Rate: 0.5 mg/kg/min (0.005 mL/kg/min) for the first 15 minutesMaintenance Infusion Rate (if tolerated) Increase gradually every 15 minutes (if tolerated) up to 8 mg/kg/min (0.08 mL/kg/min)	<ul style="list-style-type: none">Initial Infusion Rate: 0.5 mg/kg/min for the first 10 minutesMaintenance Infusion Rate (if tolerated): Increase every 20 minutes (if tolerated) by 0.8 mg/kg/min up to 6 mg/kg/min	<ul style="list-style-type: none">PIDD: 0.5 mL/kg/hr; rate can be increased every 30 min to a rate of 5 mL/kg/hr as tolerated*MMN: 0.5mL/kg/hr, rate can be increased to 5.4 mL/kg/hr as toleratedCIDP: 0.5 mL/kg/hr, rate may be increased if tolerated up to 5.4 mL/kg/hr	<ul style="list-style-type: none">PIDD and ITP: 0.01 mL/kg/min for 30 min; can be gradually increased to a maximum of 0.08 mL/kg/min if no adverse reaction*CIDP: 0.02 mL/kg/min for 20 min; can be gradually increased to a maximum of 0.08 mL/kg/min if no adverse reaction*	<ul style="list-style-type: none">5%: 0.5 mg/kg/min (0.01mL/kg/min) for the first 15 min; if tolerated, gradually increase to 4 mg/kg/min (0.08 mL/kg/min)*10%: 0.5 mg/kg/min (0.01 mL/kg/min) for the first 15 min; if tolerated, gradually increase to 8 mg/kg/min (0.08 mL/kg/min)*	<ul style="list-style-type: none">PIDD and ITP: 0.01 mL/kg/min for 30 min; can be gradually increased to a maximum of 0.08 mL/kg/min if no adverse reaction*CIDP: 0.02 mL/kg/min for 20 min; can be gradually increased to a maximum of 0.08 mL/kg/min if no adverse reaction*	<ul style="list-style-type: none">5%: 0.5 mg/kg/min (0.01 mL/kg/min) for 30 min, then advance to 1 mg/kg/min (0.02 mL/kg/min) for 30 min then advance to 2 mg/kg/min (0.04 mL/kg/min) for 30 min. Maximum rate of less than 3.33 mg/kg/min (0.07 mL/kg/min) for the remainder of the infusion.*10%: ITP 1.0 mg/kg/min (0.01 mL/kg/min) up to 12.0 mg/kg/min (Up to 0.12 mL/kg/min)* DM:1.0 mg/kg/min (0.01 mL/kg/min) up to 4.0 mg/kg/min (up to 0.04 mL/kg/min)*	<ul style="list-style-type: none">PIDD: Initial Infusion Rate: 1 mg/kg/min (0.01 mL/kg/min) Maximum Infusion Rate: 14 mg/kg/min (0.14 mL/kg/min)ITP: Initial Infusion Rate: 1 mg/kg/min (0.01 mL/kg/min) Maximum Infusion Rate: 8 mg/kg/min (0.08 mL/kg/min)CIDP: Initial Infusion Rate: 1 mg/kg/min (0.01 mL/kg/min) Maximum Infusion Rate: 12 mg/kg/min (0.12 mL/kg/min)	<ul style="list-style-type: none">PIDD and CIDP: 0.5 mg/kg/min (0.005 mL/kg/min); if well tolerated, may increase gradually to 8 mg/kg/min (0.08 mL/kg/min)*ITP: 0.5 mg/kg/min (0.005 mL/kg/min); if well tolerated, may increase gradually to 4 mg/kg/min (0.04 mL/kg/min)*	<ul style="list-style-type: none">First Infusion Initial Infusion Rate: 0.5 mg/kg/min (0.005 mL/kg/min) for 30 minutesFirst Infusion Maintenance Infusion Rate (if tolerated): Gradually increase every 30 minutes up to 3.0 mg/kg/min (0.03 mL/kg/min)From 2nd Infusion Initial Infusion Rate: 0.5 mg/kg/min (0.005 mL/kg/min) for 30 minutesFrom 2nd Infusion Maintenance Infusion Rate (if tolerated): Gradually increase up to 13 mg/kg/min (0.13 mL/kg/min)	
Sugar Content	Sugar free; stabilized with glycine	Sugar free; stabilized with glycine	No added sugars	Sugar free; stabilized with glycine	Sugar free; stabilized with glycine	<ul style="list-style-type: none">5%: 5 g D-Sorbitol in 100 mL of buffer solution10%: Sugar free, stabilized with glycine and polysorbate 80	Sugar free; stabilized with glycine	5%: 100 mg/mL maltose ¹ 10%: 90 mg/mL maltose	Glycine	Sugar free; stabilized with L-proline	Sugar free; stabilized with glycine and polysorbate 80	
Sodium Content	N/A	100–140 mmol/L	100–140 mmol/L	N/A	Trace amounts	<ul style="list-style-type: none">5%: 0.2 g sodium acetate and 0.3 g sodium chloride in 100 mL of buffer solution10%: <30 mM sodium chloride in 100 mL of buffer solution	Trace amounts	<30 mmol/L	Trace amounts	<1 mmol/L (10% solution)	N/A	
Osmolality/ Osmolarity	240-360 mOsm/kg	370–510 mOsm/kg	≤510 mOsm/kg	240–300 mOsm/kg	258 mOsm/kg	<ul style="list-style-type: none">5%: Typically 420-500 mOsm/kg (not less than 240 mOsm/kg)10%: Typically 280 mOsm/kg (not less than 240 mOsm/kg)	258 mOsm/kg	310–380 mOsm/kg	240-310 mOsmol/kg	320 mOsm/kg (range 240–440)	280 to 380 mOsmol/kg	
pH	4.5–5.5	4.0–4.6	4.0–4.6	4.6–5.1	4–4.5	<ul style="list-style-type: none">5%: 4.8-5.110%: 4.9-5.2	4–4.5	5%: 5.1–6 10%: 4.5-5	4.5–5.0	4.8 (range 4.6–5)	4.4 to 5.2	
IgA Content	≤100 mcg/mL	≤200 mcg/mL	≤200 mcg/mL	37 mcg/mL	46 mcg/mL	<ul style="list-style-type: none">5%: <10 mcg/mL10%: <20 mcg/mL	46 mcg/mL	5%: ≤200 mcg/mL 10%: 106 mcg/mL	Average 100 mcg/mL	≤25 mcg/mL	≤300 mcg/mL	
% IgG	≥96%	≥96%	≥96%	>98%	>98%	<ul style="list-style-type: none">5%: >95%10%: >98%	>98%	≥96%	≥96%	>98%	≥96%	
Latex Content	Latex free	Latex free	Latex free	Latex free	Latex free	Latex free	Latex free	Latex free	Latex free	Latex free	Latex free	
Method of Production and Viral Inactivation/ Removal Process	Modified Cohn-Oncley fractionation, anion and cation exchange chromatography, fractionation I+III, solvent/detergent treatment, and 20mm nanofiltration	Precipitation and removal of fraction III during the cold ethanol process, SD, 35 nm nanofiltration, low pH	Cohn-Oncley fractionation, anion exchange chromatography; precipitation and removal of fraction III of the cold ethanol process, solvent/detergent treatment, 35 nm nanofiltration	Cold ethanol fractionation, 35 nm nanofiltration, chromatography, low pH incubation, solvent/detergent treatment	Depth filtration, cold ethanol fractionation, chromatography, low pH treatment, caprylate precipitation	S/D treatment, virus filtration, pH incubation	Depth filtration, cold ethanol fractionation, chromatography, low pH treatment, caprylate precipitation	Low pH treatment, Cold ethanol fractionation, ultrafiltration and chromatography as well as S/D treatment	Cold ethanol fractionation process followed by purification methodologies, as well as S/D treatment, ion-exchange chromatography, and nanofiltration (20 nm)	Depth filtration, cold ethanol fractionation, octanoic acid fractionation, chromatography, pH4 incubation, 20 nm nanofiltration	Cold ethanol fractionation, caprylic acid precipitation, as well as anion and cation exchange chromatography, low pH treatment, anion exchange chromatography (AEX) and nanofiltration	
Filtration	No filter required	No filter required	No filter required	Filter optional	No filter required	No filter required	No filter required	0.2-200 micron filter optional	0.2-200 micron filter optional	No filter required	No filter required	
Flushing Compatibility	Saline or dextrose	N/A	Saline	Saline or dextrose; Do not dilute with saline	Saline or dextrose; Do not dilute with saline	Saline or dextrose	Saline or dextrose	Saline or dextrose	Saline or dextrose	Saline or dextrose	N/A	
Storage Requirements	<ul style="list-style-type: none">Refrigerate or room temperatureDo not freezeDo not return to refrigerator after stored at room temperature	<ul style="list-style-type: none">Refrigerate between 2°C–8°C (36°F to 46°F)Do not freeze or heat. Do not use any solutions that have been frozen or heated. Do not use after expiration date	<ul style="list-style-type: none">Refrigerate between 2°C–8°C (36°F to 46°F)Do not freeze or heat. Do not use any solutions that have been frozen or heated. Do not use after expiration date	<ul style="list-style-type: none">Refrigerate or room temperatureDo not freeze	<ul style="list-style-type: none">Refrigerate or room temperatureDo not freeze	<ul style="list-style-type: none">Refrigerate or room temperatureDo not freeze	<ul style="list-style-type: none">Refrigerate or room temperatureDo not freeze	<ul style="list-style-type: none">Refrigerate or room temperatureDo not freeze	<ul style="list-style-type: none">5%: Maintain temperature +2°C to + 25°C (36°F to 77°F). Do not freeze10%: Store at refrigerated temperature 2°C–8°C (36°F to 46°F). Do not freeze	<ul style="list-style-type: none">Refrigerate 2°C to 8°C (36°F to 46°F)Do not freeze	<ul style="list-style-type: none">Room temperatureDo not freezeProtect from light	<ul style="list-style-type: none">Refrigerate between 2°C to 8°C (36°F to 46°F)Do not freeze
Shelf Life	36 months refrigerated 2°C–8°C (36°F to 46°F), or 24 months room temperature 8°C-25°C (46°C–77°C)	Refer to package label	Refer to package label	36 months refrigerated at 2C°–8°C (36F°–46°F), or 24 months at room temp (≤25°C, 77°F)	36 months refrigerated at 2°–8° C (36F°–46°F), or 6 months at room temp (≤25°C, 77°F) any time during the 36 months	36 months, when stored between 2°C (35.6°F) and 25°C (77°F)	36 months refrigerated at 2°C–8°C (36°F–46°F), or 6 months at room temp (≤25°C, 77°F) any time during the 36 months	<ul style="list-style-type: none">5%: 24 months, at +2°C to + 25°C (36°F to 77°F) from the date of manufacture. Preservative free.10%: 36 months; within this shelf life, the product may be stored up to 9 months at ≤25°C (77°F). Preservative free.	36 months at 2°C to 8°C (36°F to 46°F) from the date of manufacture. Within its shelf life, the product may be stored at ≤ 25°C (77°F) for up to 12 months. Preservative free.	36 months, preservative free	Do not use after expiration date. Within the expiration date, the product may be stored at room temperature (more than 8°C and up to 25°C/ more than 46°F and up to 77°F) for a single period not exceeding 6 months. Once the product has been taken out of the refrigerator, it must not be returned to the refrigerator; preservative free	

1. Maltose can interfere with the readings of some blood glucose monitoring systems up to 24–36 hours post-dose.

The information contained in this communication is provided in summary form. It is not intended for use as the sole basis of clinical treatment, as a substitute for reading the original research, nor as a substitute for the knowledge, skill and judgment of the medical provider. This list is subject to change. CVS Specialty assumes no liability whatsoever for the information provided or for any diagnosis or treatment made as a result of this information. The information noted in this brochure was taken from the manufacturers' prescribing information. It does not contain all information needed to use these products safely and effectively. See the manufacturers' package insert for full prescribing information. CVS Health and/or its affiliates does not provide medical advice and does not recommend a particular treatment or brand. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Specialty.